Light Chain Cast Nephropathy Myeloma Kidney

Slide 1 · Light-Chain Cast Nephropathy

(“Myeloma Kidney”)

Tubular obstruction, light-chain toxicity, and clinicopathologic diagnosis

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain the two principal mechanisms of light-chain–mediated tubular injury.

Recognize cast morphology and the associated tubulointerstitial response.

Distinguish cast nephropathy from AL amyloidosis and light-chain deposition disease.

Integrate clinical presentation, urine findings, and the indication for renal biopsy.

Slide 3 · The clinical entity is a tubulointerstitial disease

Filtered monoclonal immunoglobulin free light chains can damage renal tubular epithelium.

Their precipitation with urinary glycoprotein produces obstructive intratubular casts.

Tubular injury, inflammatory reaction, and interstitial fibrosis explain renal dysfunction.

Slide 4 · Renal disease associated with nonrenal malignancy

Mechanism

Selected causes

Renal compartment

Direct invasion / obstruction

Renal parenchymal deposits; Ureteral obstruction

Parenchymal / postrenal

Systemic tumor complications

Hypercalcemia; Hyperuricemia

Tubular / interstitial

Abnormal proteins

Myeloma light chains; AL amyloid

Tubular or glomerular

Treatment / infection

Therapies, transplant, opportunistic infection

Variable

Slide 5 · Myeloma kidney is not one lesion

Cast nephropathy: Intratubular light-chain complexes and tubulointerstitial damage.

AL amyloidosis: Deposits of light-chain–derived amyloid.

Light-chain deposition disease (LCDD): Nonfibrillar deposits in glomerular and tubular basement membranes.

Hypercalcemia, hyperuricemia, infection, and treatment toxicity may coexist.

Slide 6 · Where does the abnormal protein originate?

Clonal plasma-cell proliferation

Monoclonal immunoglobulin/light-chain secretion

Filtered circulating free light chains

Tubular epithelial injury ± cast formation

Conceptual sequence (simplified; Arrows indicate causal direction)

Slide 7 · Bence-Jones proteinuria: The relevant substrate

Bence-Jones proteins are urinary immunoglobulin light chains.

The degree of light-chain proteinuria correlates with renal dysfunction account.

The intrinsic physicochemical behavior of the light chain affects its tubular toxicity.

Slide 8 · Two parallel injury mechanisms

Direct epithelial toxicity

Some monoclonal light chains are injurious to tubular cells.

Toxicity varies with the properties of the individual protein.

Cast-mediated obstruction

Light chains combine with Tamm–Horsfall protein in urine.

Bulky intratubular casts obstruct flow and provoke inflammation.

Slide 9 · Simplified nephron route of filtered light chains

Glomerular filtration

Proximal tubular exposure

Distal nephron: Tamm–Horsfall interaction

Cast obstruction + local injury

Native PowerPoint schematic — not microscopy

Slide 10 · Why tubular light-chain exposure increases

A monoclonal plasma-cell disorder increases the circulating light-chain burden.

Light chains enter the glomerular filtrate and are delivered to the tubules.

A sufficiently large or nephrotoxic filtered load overwhelms normal handling.

Slide 11 · Mechanism 1: Directly nephrotoxic light chains

Excess luminal free light chains

Direct epithelial toxicity

Tubular cellular injury

Decline in tubular function / kidney function

Conceptual sequence (simplified; Arrows indicate causal direction)

Slide 12 · Protein chemistry matters

Renal risk is not determined by the diagnosis of myeloma alone.

The amount of excreted light chain and its molecular behavior both matter.

Different light chains can preferentially produce casts, deposition, or amyloid pathology.

Slide 13 · Tamm–Horsfall protein is the cast partner

Tamm–Horsfall urinary glycoprotein is also called uromodulin.

Light chains combine with this protein to form larger intratubular complexes.

The casts are a specific pathologic consequence of abnormal urinary protein interactions.

Slide 14 · Mechanism 2: Development of an obstructive cast

High urinary light-chain concentration

Interaction with Tamm–Horsfall glycoprotein

Precipitation and cast enlargement

Luminal distension and obstruction

Conceptual sequence (simplified; Arrows indicate causal direction)

Slide 15 · Why acidic urine promotes cast formation

Light-chain–Tamm–Horsfall aggregation under acidic conditions.

The resulting aggregates become large, histologically recognizable tubular casts.

Obstruction is coupled to local epithelial and inflammatory injury.

Slide 16 · Tubular obstruction is more than a passive plug

Complexes aggregate in tubular lumen

Cast fills and stretches the lumen

Tubular flow falls; Adjacent cells are injured

Inflammation surrounds affected segments

Native PowerPoint schematic — not microscopy

Slide 17 · Why dehydration can precipitate injury

Reduced tubular water delivery concentrates the urinary light-chain load.

Concentrated luminal proteins are more likely to form obstructive aggregates.

Volume depletion can therefore convert a vulnerable kidney into abrupt renal dysfunction.

Slide 18 · Hypercalcemia provides a second hit

Myeloma-associated hypercalcemia

Impaired renal concentrating physiology / volume loss

Reduced tubular flow and concentrated solutes

Greater susceptibility to light-chain cast injury

Conceptual sequence (simplified; Arrows indicate causal direction)

Slide 19 · Infection and drug exposure can trigger AKI

Acute infection is a textbook-listed precipitant of abrupt renal deterioration.

Nephrotoxic antibiotics are another documented trigger.

A superimposed insult may coexist with direct light-chain injury and tubular casts.

Slide 20 · Renal hazards in a patient with myeloma

Hazard

Plausible renal effect

Clinical interpretation

Light-chain proteinuria

Tubular toxicity; Obstructive casts

Primary cast-nephropathy mechanism

Hypercalcemia

Volume / tubular disturbances

Amplifies susceptibility

Hyperuricemia

Additional tubular stress

Potential cofactor

Acute infection / antibiotics

Acute superimposed injury

May precipitate oliguria

Slide 21 · From casts to interstitial scarring

Intraluminal protein cast

Tubular epithelial damage

Inflammatory and macrophage reaction

Interstitial fibrosis and chronic functional loss

Conceptual sequence (simplified; Arrows indicate causal direction)

Slide 22 · The kidney can suffer several insults simultaneously

Tubular casts can coexist with AL amyloid, LCDD, or nephrocalcinosis.

Infection and treatment-related injury can modify the biopsy and the clinical course.

Attributing all renal impairment to “myeloma kidney” without phenotyping may be misleading.

Slide 23 · Two clinical trajectories are described

Insidious chronic kidney disease can progress over months to years.

An abrupt presentation may manifest as acute kidney injury with oliguria.

The same systemic plasma-cell disorder can produce either trajectory.

Slide 24 · Chronic versus acute presentation

Insidious decline

Renal function worsens over months to years.

Interstitial fibrosis can accompany sustained tubular injury.

Abrupt AKI

Oliguria may occur.

Consider dehydration, hypercalcemia, infection, and nephrotoxic antibiotics.

Slide 25 · Chronic renal dysfunction: Morphologic correlate

Persistent tubular injury is followed by an interstitial inflammatory response.

Fibrosis within the tubulointerstitial compartment can accumulate.

This chronic change provides a structural basis for progressive renal impairment.

Slide 26 · Acute oliguria: Identify the precipitant

Ask about recent fluid losses or reduced intake.

Review hypercalcemia, intercurrent infection, and nephrotoxic antibiotic exposure.

Interpret acute deterioration as potentially multifactorial rather than one isolated cast event.

Slide 27 · The biopsy target is principally tubular

The distinctive material is located inside tubular lumens.

The affected tubules become dilated or distended by casts.

Adjacent interstitial inflammation is a defining companion to the luminal lesion.

Slide 28 · Morphology: Irregular casts inside distended tubules

Schematic — NOT a histologic specimen

Identify:

Amorphous intratubular material

Irregular / angulated outline

Luminal expansion

Epithelial boundary

Slide 29 · Cast color on routine histology

Bence-Jones casts as pink-to-blue amorphous masses.

Color may vary within or between casts; Do not require a single hue.

Location, contour, fracture pattern, and tissue reaction strengthen recognition.

Slide 30 · Fractures and lamination are morphologic clues

Schematic — NOT a histologic specimen

Identify:

Angular fractured cast planes

Optional concentric lamination

Intraluminal location

Reactive cells outside tubule

Slide 31 · Why “fractured” casts matter

Light-chain casts are often broken into irregular, angular segments.

Their brittle-appearing contours are a useful recognition clue on H&E.

Morphology must be interpreted alongside clinical monoclonal-protein evidence.

Slide 32 · Macrophage reaction around casts

Activated macrophages can accumulate at affected tubules.

Some fuse into multinucleated giant cells surrounding cast material.

This reaction helps explain the striking tubulointerstitial inflammatory appearance.

Slide 33 · Tubular rupture produces a granulomatous pattern

Tubular wall break

Schematic — NOT a histologic specimen

Identify:

Cast-filled damaged tubule

Tubular wall disruption

Extravasated cast fragments

Giant cells / macrophages around leaked material

Slide 34 · Tubular rupture intensifies tissue injury

Casts may breach a damaged tubular wall.

Extravasated material elicits a granulomatous inflammatory response.

Inflammation is therefore not limited to the lumen of an intact tubule.

Slide 35 · Interstitial inflammation and fibrosis

Inflammatory cells commonly involve tissue adjacent to abnormal casts.

Interstitial fibrosis is often present in established disease.

The tubulointerstitial reaction contributes to lasting loss of renal function.

Slide 36 · Read the renal biopsy systematically

Compartment

Examine for

Reason

Tubular lumens

Amorphous irregular fractured casts

Direct cast-related evidence

Tubular lining

Epithelial injury and luminal distension

Explains dysfunction

Interstitium

Inflammation, giant cells, fibrosis

Local response / chronicity

Glomeruli / vessels

Evidence of another concurrent lesion

Avoid single-cause attribution

Slide 37 · Integrated lesion: Cast plus epithelial and interstitial damage

Monoclonal cast in tubule

Distension and epithelial damage

Peritubular giant-cell response

Interstitial fibrosis

Native PowerPoint schematic — not microscopy

Slide 38 · A fractured cast alone is not the complete diagnosis

Protein casts occur in other renal diseases.

A characteristic cast pattern is more convincing when paired with monoclonal light-chain evidence.

Correlate biopsy morphology with plasma-cell disease and the renal presentation.

Slide 39 · Separate luminal casts from deposited light chains

Cast nephropathy: Aggregated protein occupies the tubular lumen.

LCDD: Nonfibrillar light-chain material deposits in basement membranes.

AL amyloidosis: Light-chain–derived amyloid forms a distinct tissue-deposit disease.

Slide 40 · Three major myeloma-related light-chain lesions

Lesion

Principal material / site

Characteristic concept

Cast nephropathy

Light-chain–uromodulin casts in tubules

Obstruction + inflammation

AL amyloidosis

Amyloid from free light chains

Tissue amyloid deposition

LCDD

Nonfibrillar light chains in GBM, mesangium, TBM

Glomerular and tubular basement-membrane injury

Slide 41 · AL amyloidosis: A different protein lesion

Renal amyloid in myeloma is usually derived from monoclonal free light chains.

An AL amyloidosis frequency of 6%–24% among individuals with myeloma.

This is a tissue-deposit mechanism, not synonymous with intratubular casts.

Slide 42 · Light-chain deposition disease (LCDD)

Nonfibrillar light chains can deposit in GBM and mesangium.

The same process can involve tubular basement membranes.

LCDD produces a glomerulopathy and may contribute to tubulointerstitial nephritis.

Slide 43 · The light-chain isotype pattern is a clue—not a rule

AL amyloidosis

Usually λ-type light chains description.

Confirm disease by actual deposition phenotype.

Light-chain deposition disease

Usually κ-type light chains description.

Do not diagnose LCDD from isotype alone.

Slide 44 · Renal protein type helps localize the injury

The frequency of Bence-Jones light-chain proteinuria.

Substantial non–light-chain proteinuria (e.g., albuminuria) suggests AL amyloid or LCDD.

Protein pattern is a clinical clue; Overlapping lesions remain possible.

Slide 45 · Textbook frequency statements: Interpret carefully

Textbook statement

Reported amount

Teaching interpretation

Renal insufficiency in myeloma / related disorders

About half

Overall renal involvement; Multiple mechanisms

Bence-Jones proteinuria in myeloma

About 70%

Urinary light chain, not proof of a cast lesion

AL amyloidosis in myeloma

6%–24%

Separately characterized renal/systemic lesion

Slide 46 · A positive light-chain test does not locate a renal lesion

Urinary monoclonal light chains support the presence of a monoclonal protein burden.

They do not prove whether the kidney contains casts, amyloid, or basement-membrane deposits.

The pattern of proteinuria and, when indicated, biopsy clarify the renal phenotype.

Slide 47 · Concurrent lesions are an expected diagnostic possibility

A patient may have cast nephropathy together with amyloid or LCDD.

Nephrocalcinosis and infection can also be present.

The final clinicopathologic assessment should identify all material contributors.

Slide 48 · 2023 IMWG: Basic assessment of renal impairment

Measure serum creatinine and estimate the glomerular filtration rate.

Obtain serum free light chains.

Obtain 24-hour urinary total protein, electrophoresis, and immunofixation.

Slide 49 · 2023 IMWG: Clinical diagnostic pathway

Myeloma + renal impairment

Creatinine / eGFR + serum FLC

24-hour urinary protein analysis

Determine whether a renal biopsy is needed

Conceptual sequence (simplified; Arrows indicate causal direction)

Slide 50 · 2023 IMWG: Why quantify albuminuria?

Predominant albuminuria raises suspicion of glomerular involvement.

AL amyloidosis and light-chain deposition disease are important alternatives.

The urine protein pattern changes the need to examine tissue directly.

Slide 51 · 2023 IMWG: When kidney biopsy is advised

Consider biopsy for nonselective proteinuria, mainly albuminuria.

Biopsy is advised when involved serum free light chains are below 500 mg/L and the cause remains uncertain.

Exclude other causes of renal impairment when applying the recommendation.

Slide 52 · How to interpret the 500 mg/L recommendation

What it DOES indicate

Below 500 mg/L, biopsy has heightened importance when renal impairment is unexplained.

Interpret together with urine protein pattern and competing renal causes.

What it DOES NOT mean

It does not histologically define cast nephropathy.

It is not a guarantee that injury is absent above or below the value.

Slide 53 · Why a renal biopsy changes the diagnosis

The renal lesions of monoclonal proteins are mechanistically different.

Biopsy can establish a tissue pattern when clinical/urine findings are ambiguous.

It can also identify fibrosis or a coexisting non–light-chain cause.

Slide 54 · 2023 IMWG: Early management priorities

Rapid suppression of the causal plasma-cell light-chain production is central.

Supportive care and high-dose dexamethasone are included in the IMWG recommendations.

Bortezomib-based regimens are a cornerstone of treatment in newly diagnosed renal impairment.

Slide 55 · Therapeutic logic follows the mechanism

Treat the plasma-cell clone

Reduce circulating free light chains

Lower filtered tubular protein burden

Create opportunity for renal recovery

Conceptual sequence (simplified; Arrows indicate causal direction)

Slide 56 · Correct reversible aggravating factors

Assess and correct dehydration when clinically appropriate.

Identify hypercalcemia, infection, and renal-toxic drug exposure.

Avoid interpreting oliguria without evaluating the combined renal insults.

Slide 57 · 2023 IMWG: Mechanical light-chain removal

Extracorporeal techniques can remove circulating light chains in selected settings.

IMWG reports that mechanical approaches do not improve overall survival.

Such techniques do not replace effective anti-myeloma treatment and supportive care.

Slide 58 · What treatment can and cannot reverse

Potentially modifiable early injury

Lower light-chain delivery.

Correct hemodynamic and metabolic precipitants.

Potentially persistent injury

Established tubulointerstitial fibrosis.

Coexisting AL amyloid or light-chain deposits.

Slide 59 · Clinical problem 1: Abrupt oliguria

A patient with known myeloma develops oliguria after dehydration and an acute infection. Which mechanisms should be considered?

A. Only glomerular immune-complex disease

B. Cast nephropathy plus superimposed precipitating factors

C. Amyloid is the only possible renal mechanism

Instructor answer and rationale are in the speaker notes.

Slide 60 · Case 1: Clinicopathologic reasoning

A large filtered light-chain burden makes tubular cast injury plausible.

Volume depletion concentrates tubular contents; Infection may add renal stress.

Urine studies and serum free light chains clarify the protein burden; Biopsy depends on the clinical picture.

Slide 61 · Clinical problem 2: Marked albuminuria

A patient with monoclonal gammopathy has renal dysfunction and prominent albuminuria. Which diagnosis deserves particular consideration?

A. AL amyloidosis or LCDD

B. Pure cast nephropathy is proven

C. All renal pathology is excluded

Instructor answer and rationale are in the speaker notes.

Slide 62 · Case 2: Discriminating the lesion

Albuminuria suggests that the glomerular compartment may be importantly involved.

AL amyloidosis and LCDD have distinct deposited-protein pathology.

2023 IMWG recommends biopsy when nonselective proteinuria makes the lesion uncertain.

Slide 63 · Morphology problem: Fractured casts

A biopsy description reports angulated, fractured intratubular material with multinucleated giant cells. Which entity is most strongly suggested?

A. Light-chain cast nephropathy

B. Minimal-change disease

C. Ureteral obstruction alone

Instructor answer and rationale are in the speaker notes.

Slide 64 · Morphology problem: What can coexist?

The biopsy may additionally show AL amyloid, LCDD, or nephrocalcinosis.

The adjacent interstitium may display both inflammation and established fibrosis.

An integrated report should not stop at the recognition of the cast material.

Slide 65 · A high-yield differential of renal injury

Clinical / pathologic clue

Cast nephropathy

Alternative to consider

Fractured luminal casts, giant cells

Strongly supports

Other protein casts if context atypical

Substantial albuminuria

Not the classic isolated pattern

AL amyloid / LCDD

Nonfibrillar basement-membrane deposits

Not the defining cast lesion

LCDD

Abrupt AKI after dehydration

Compatible

Hemodynamic or toxic AKI also possible

Slide 66 · Diagnostic traps to avoid

Do not call every light-chain–related renal disease “cast nephropathy.”

Do not regard Bence-Jones proteinuria alone as histologic confirmation.

Do not overlook albuminuria or competing causes of acute kidney injury.

Do not mistake the 500 mg/L IMWG biopsy recommendation for a histologic threshold.

Slide 67 · Synthesis: Follow the causal chain

Plasma-cell light-chain production

Direct toxicity + uromodulin-associated casts

Tubular damage, obstruction, inflammation

AKI / progressive chronic kidney disease

Conceptual sequence (simplified; Arrows indicate causal direction)

Slide 68 · Five points to retain

Cast nephropathy is principally a monoclonal light-chain tubulointerstitial injury.

Renal dysfunction results from both direct light-chain toxicity and obstructive cast formation.

Fractured casts, giant cells, and adjacent inflammation are morphologic clues.

AL amyloid and LCDD are distinct, sometimes concurrent renal lesions.

Clinical evaluation must integrate protein pattern, FLC burden, and other renal insults.

Slide 69 · Selected references

Reference

Role

Where to look

Robbins, Cotran & Kumar, 11th ed. (2026)

Primary pathology source

Chapter 20, pp. 850–851

Robbins, Cotran & Kumar, 11th ed. (2026)

Hematologic parent context

Chapter 13, pp. 553–554

Dimopoulos MA et al. Lancet Oncol. 2023

IMWG renal evaluation / treatment

doi:10.1016/S1470-2045(23)00223-1

Menè P et al. Int J Nephrol Renovasc Dis. 2022

Supplementary morphology / mechanism

doi:10.2147/IJNRD.S280179